

01-28-02

Attorney Docket No.: D0590/7011 (JRV) AJC658 U.S. PTO  
01/25/02**UTILITY  
PATENT APPLICATION  
TRANSMITTAL***(Only for new nonprovisional applications  
under 37 CFR 1.53(b))*

Attorney Docket No.

**D0590/7011**

First Named Inventor or Application Identifier

**Plaetinck et al.**

Express Mail Label No.

**EL711220616US**

Date of Deposit

**January 25, 2002**JC658 U.S. PTO  
01/25/02  
10/057108**APPLICATION ELEMENTS***See MPEP chapter 600 concerning utility patent application contents*

1. ☒ Fee Transmittal Form  
*(Submit an original, and a duplicate for fee processing)*
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.  
☐ Statement filed in prior application, status still proper and desired.
3. ☒ Specification -Total pages 66  
58 - pages description  
1 - page abstract  
7 - pages claims                      70 - Total claims
4. ☒ Drawing(s) (35 USC 113)    21 - Total sheets  
☒ Informal    ☐ Formal    19 - Total drawings
5. ☒ Oath or Declaration                      3 - Total pages  
a. ☐ Newly executed (original or copy)  
b. ☒ Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 18 completed)*  
*[Note Box 6 below]*  
i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Incorporation by Reference  
*(usable if Box 5b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. **See 19.**
7. ☐ Application Data Sheet, See 37 CFR 1.76

**ADDRESS**Box Patent Application  
TO: Commissioner for Patents  
Washington, DC 20231

8. ☐ CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)
9. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☒ Computer Readable Form (see item 18)
  - b. ☒ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ paper (identical to computer copy)
  - c. ☒ Statement verifying identity of above

**ACCOMPANYING APPLICATION PARTS**

10. ☐ Assignment Papers/cover sheet & documents(s)
11. ☐ 37 CFR 3.73(b) Statement  
*(when there is an assignee)*  
☐ Power of Attorney
12. ☐ English Translation of Document *(if applicable)*
13. ☒ Information Disclosure Statement/PTO-1449  
☐ Copies of IDS Citations
14. ☒ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*
16. ☐ Certified Copy of Priority Document(s)  
*(if foreign priority is claimed)*
17. ☐ Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)
18. ☒ Other: Copy of face of earlier filed Computer Readable Form (CRF), and Letter Requesting Use of Computer Readable Form From Another Application. Also, Request for Early Publication Under 37CFR §1.219

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 09/347,311 filed on July 2, 1999, entitled CHARACTERISATION OF GENE FUNCTION USING DOUBLE STRANDED RNA INHIBITION and now pending.

☐ Cancel in this application claims \_\_\_\_\_ before calculating the filing fee.

☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:

--This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.--

**Prior application information:** Examiner M. Penn Group Art Unit: 1633

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

20. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	
DATE	January 25, 2002

Inventor(s): Plaetinck et al.

Serial No: Not assigned

Filed: Herewith (January 25, 2002)

CHECK BOX, if applicable:

For: CHARACTERISATION OF GENE FUNCTION USING DOUBLE  
STRANDED RNA INHIBITION☐ **DUPLICATE****Fee Calculation Sheet**

CLAIMS	FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
	TOTAL CLAIMS (37 CFR 1.16(c))	70-20=	41x	\$ 18	= \$ 1260.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	6-3=	3 x	\$ 84	= \$ 252.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) +			\$270.00	= \$ 270.00
				BASIC FEE (37 CFR 1.16(a))	\$ 740.00
	Fee for Petition for Extension of Time (if any)				\$
	Total of above Calculations =				\$ 2,522.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				\$
	Assignment Recordation Fee (if any)				\$
	Other Fees (if any).				\$ 300.00
	TOTAL =				\$ 2,822.00

1. A check in the amount of \$2,822.00 is enclosed.

**General Authorization to Charge Deposit Account and General Request for Extension of Time**

2. a. ☒ If the filing of any paper in this application necessitates the payment of a fee under 37 CFR §§ ☒ 1.16 ☒ 1.17 or ☒ 1.18, and the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.
- b. ☐ The applicant hereby revokes any prior authorization to charge a fee due under 37 CFR §§ ☐ 1.16 ☐ 1.17 or ☐ 1.18.
3. If the filing of any paper in this application necessitates an extension of time under 37 CFR § 1.136(a), the applicant hereby requests such extension of time. If the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

  
 John R. Van Amsterdam, Reg. No. 40,212  
 Wolf, Greenfield & Sacks, P.C.  
 600 Atlantic Avenue  
 Boston, MA 02210-2211  
 (617) 720-3500  
 Attorneys of Record

Docket No. D0590/7011 (JRV)  
 Date: January 25, 2002

Attorney's Docket No. **D0590/7011**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Plaetinck et al.  
Serial No : Not assigned  
Filed : Herewith (January 25, 2002)  
For : CHARACTERISATION OF GENE FUNCTION USING DOUBLE  
STRANDED RNA INHIBITION  
Examiner : Not assigned  
Art Unit : Not assigned

Box PATENT APPLICATION  
Commissioner for Patents  
Washington, D.C. 20231

**LETTER REQUESTING USE OF COMPUTER READABLE FORM**  
**FROM ANOTHER APPLICATION**


Sir:

In accordance with 37 C.F.R. §1.821(e) regarding submission of a computer readable form of nucleotide and/or amino acid sequence disclosures in a new application which corresponds to the sequence information from another application already on file at the United States Patent and Trademark Office, Applicants request use of the previously filed computer readable form. The Sequence Listing enclosed herewith is identical to that filed on January 4, 2001 in a previous application, Serial No. 09/347,311, which is the parent application of the divisional application filed herewith. In accordance with 37 C.F.R. 1.821(e), please use the last-filed computer readable form filed in application Serial No. 09/347,311 as the computer readable form for the instant application. It is understood that the U.S. Patent and Trademark Office will make the necessary change in application number, docket number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing for the instant application is included herewith. Applicants' attorney states that the paper copy filed herewith and the computer readable form filed in application Serial No. 09/347,311 are identical and contain no new matter.

The computer readable form was filed as a 3½ inch diskette containing the file 502850\_1.txt in ASCII text format. A copy of the face of the computer disk is enclosed.

Respectfully submitted,

By:



John R. Van Amsterdam, Reg No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Telephone (617) 720-3500

Docket No. D0590/7011  
Dated: January 25, 2002  
**xNDD**

*Express Mail No. EL711220616US*  
*Date of Deposit: January 25, 2002*

Attorney's Docket No. **D0590/7011**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Plaetinck et al.  
Serial No : Not assigned  
Filed : Herewith (January 25, 2002)  
For : CHARACTERISATION OF GENE FUNCTION USING DOUBLE  
STRANDED RNA INHIBITION

BOX PATENT APPLICATION  
Commissioner for Patents  
Washington, DC 20231


**REQUEST FOR EARLY PUBLICATION UNDER 37 CFR § 1.219**

Sir:

Applicants hereby request that the above-identified application, filed herewith, be published as soon as possible.

The publication fee set forth in 37 CFR § 1.18(d) is enclosed herewith.

Respectfully submitted,

By:   
John R. Van Amsterdam, Reg No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Telephone (617) 720-3500

Docket No. D0590/7011  
Dated: January 25, 2002  
**xNDD**

01/31/2002 HDEMESS1 00000053 10057108  
05 FC:125 300.00 OP